Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation

Clinical Therapeutics

Volumn 25, Issue 2, 2003, Pages 515-529

  Fujioka, Ken ^a   Pans, Miranda ^b   Joyal, Steven ^b  

^a SCRIPPS CLINIC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Compliance; Diabetes; Efficacy; Extended release; Immediate release; Metformin

Indexed keywords

FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ANORECTAL DISEASE; APPETITE DISORDER; ARTICLE; BODY WEIGHT; CARDIOGENIC SHOCK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES CONTROL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; FRUCTOSAMINE BLOOD LEVEL; GALLBLADDER DISEASE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEARTBURN; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED DRUG RELEASE; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037291235     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80093-0     Document Type: Article

References (23)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
2. Texas Diabetes Council/Texas Department of Health. Glycemic control algorithm for type 2 diabetes mellitus in adults. Available at: http://www.tdh.state.tx.us/diabetes/tdc.htm. Accessed October 24, 2002.
3. Hawkins D, Bradberry JC, Cziraky MJ, et al. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: Toward better patient outcomes and new roles for pharmacists. Pharmacotherapy. 2002;22:436-444.
4. Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism. 1993;42:1217-1222.
5. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73:1294-1301.
6. DeFronzo RA, Goodman AM, for the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
7. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491-497.
8. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4059-4067.
9. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
10. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabetes Metab. 1986;12:346-350.
11. Vidon N, Chaussade S, Noel M, et al. Metformin in the digestive tract. Diabetes Res Clin Pract. 1988;4:223-229.
12. Marathe PH, Arnold ME, Meeker J, et al. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol. 2000;40:1494-1502.
13. Donahue S, Marathe P, Guld T, Meeker J. The pharmacokinetics and pharmacodynamics of the metformin extended-release tablet versus immediate-release metformin in subjects with type 2 diabetes. Diabetes. 2002;51(Suppl 2):A468. Abstract.
14. Marathe P, Turner K. Steady-state pharmacokinetics of the metformin extended-release tablet versus the immediate-release metformin tablet in healthy subjects. Diabetes. 2002;51(Suppl 2):A474. Abstract.
15. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
16. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
17. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68-71.
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
19. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460-467.
20. Cusi K, DeFronzo RA. Metformin: A review of its metabolic effects. Diabetes Rev. 1998;6:89-131.
21. Raz I, Delaet I, Goyvaerts H, et al. Safety and efficacy of a novel extended-release formulation of metformin in patients with type 2 diabetes. Diabetes. 2000;49(Suppl 1):A363. Abstract.
22. Brazg R, Decherney S, Proszynski E, et al. Safety and efficacy of a novel extended-release formulation of metformin in patients with type 2 diabetes: A dose-ranging study. Diabetes. 2000;49(Suppl 1):A99. Abstract.
23. Glucophage® and Glucophage® XR [package inserts]. Princeton, NJ: Bristol-Myers Squibb Company; 2002.